INTRODUCTION
============

*Enterobacteriaceae* species are among the most common nosocomial pathogens, causing serious infections in various organs and tissues. Currently, carbapenems are the most potent agents prescribed for the treatment of serious infections caused by *Enterobacteriaceae* species because of their broad spectra of antibacterial activity and their excellent stability to hydrolysis by most β-lactamases, including extended-spectrum β-lactamases (ESBLs) and AmpC cephalosporinases. However, the widespread use of carbapenems has led to the emergence of carbapenem-resistant *Enterobacteriaceae* species in diverse geographic locations worldwide, and this is becoming an important therapeutic challenge in the clinic setting \[[@B1]-[@B3]\].

The main mechanisms of carbapenem resistance in *Enterobacteriaceae* species include the acquisition of carbapenemases and hyperproduction of AmpC cephalosporinases, in combination with porin loss \[[@B4]\]. Carbapenemases are members of the molecular class A, B, and D β-lactamases, which have the ability to hydrolyze penicillins, cephalosporins, monobactams, and carbapenems \[[@B4]\]. Class A serine carbapenemases include 3 major families of NMC/IMI, SME, and KPC enzymes and can be inhibited by clavulanic acid and tazobactam \[[@B5]\]. Among the class A carbapenemases, KPC-2 is the most common type reported in China \[[@B6], [@B7]\]. Class B carbapenemases, also called metallo-β-lactamases (MBLs), are resistant to the commercially available β-lactamase inhibitors, such as clavulanic acid, sulbactam, and tazobactam, but susceptible to inhibition by metal ion chelators, such as EDTA, a chelator of Zn^2+^ and other divalent cations \[[@B8]\]. In the past decade, a number of acquired MBLs have been identified and categorized into 2 major groups: IMP- and VIM-type enzymes. IMP-4 and IMP-8 carbapenemases have been detected in China, and these have led to a low to moderate level of carbapenem resistance in strains of *Enterobacteriaceae* species \[[@B9]\]. The hydrolysis of carbapenems by the class D oxacillinase family is weak and leads to reduced susceptibility to imipenem and meropenem but with the minimal inhibitory concentration (MIC) still in the susceptible range, thus potentially causing detection failures \[[@B10]\].

The goals of this study were to investigate the prevalence of carbapenemase genes in clinical strains of *Enterobacteriaceae* species isolated from a university hospital, and to explore the main mechanisms of decreased susceptibility to carbapenems in these clinical strains.

METHODS
=======

1. Bacterial strains and susceptibility tests
---------------------------------------------

All patient specimens utilized in this study were from The First Affiliated Hospital of Chongqing Medical University, which has 2,500 inpatient beds and is one of the largest hospitals in the southwest of China. Samples were collected from November 2009 to December 2010. The clinical isolates were identified and the susceptibility tests were performed by using the Vitek2 Compact System with GN card and ASTGN13 card (bioMérieux, Marcy l\'Etoile, France). Strains of *Enterobacteriaceae* species with decreased susceptibility to carbapenems (MIC of imipenem, meropenem, or ertapenem ≥2 µg/mL) were consecutively collected and confirmed by the agar dilution method, according to the guidelines of the CLSI \[[@B11]\].

2. Detection of carbapenemases
------------------------------

Modified Hodge Tests (MHT) were carried out according to CLSI recommendations for phenotypic screening of carbapenemase producers among species of *Enterobacteriaceae* \[[@B11]\]. *Escherichia coli* ATCC 25922 and *Klebsiella pneumoniae* ATCC BAA-1705 were used as negative and positive controls, respectively. The class A and B carbapenemases were screened by clavulanic acid-disc synergy tests and EDTA-disc synergy tests, respectively, as previously described \[[@B12], [@B13]\].

3. PCR amplification and DNA sequencing
---------------------------------------

Total DNA was extracted from all strains by 10 min boiling of bacterial culture, followed by 1 min centrifugation at 15,000 rpm. The supernatant was collected and used for PCR amplification. The main class A, class B, and class D carbapenemase genes were amplified using the primers and conditions described in the references listed in [Table 1](#T1){ref-type="table"} \[[@B14]-[@B19]\]. In addition, 3 ESBL genes (*bla*SHV, *bla*TEM, and *bla*CTX-M) and 5 plasmid-mediated AmpC cephalosporinase genes (*bla*CYM-2, *bla*ACT-1, *bla*ACC-1, *bla*DHA-1, and *bla*FOX-1) were amplified by PCR as previously described \[[@B20], [@B21]\], and all PCR products were sequenced directly in an ABI PRISM 3730XL sequencer (Applied Biosystems, Foster City, CA, USA). DNA sequences were compared with known sequences in GenBank.

4. Strain genotyping
--------------------

We performed genotyping on all isolates, except for *Enterobacter amnigenus*, by using enterobacterial repetitive intergenic consensus (ERIC)-PCR with primers ERIC1R (5\'-ATGTAAGCTCCTGGGGATTCAC-3\') and ERIC2 (5\'-AAGTAAGTGACTGGGGTGAGCG-3\') as previously described \[[@B22]\]. Electrophoretic banding patterns were compared by visual inspection. Isolates were considered different if their profiles differed by 2 or more bands \[[@B23]\].

RESULTS
=======

1. Identification of *Enterobacteriaceae* species with decreased susceptibility to carbapenems
----------------------------------------------------------------------------------------------

From a collection of 1,472 isolates of *Enterobacteriaceae* species, we identified 18 isolates with decreased susceptibility to carbapenem treatment, including 8 isolates of *Enterobacter cloacae*, 5 isolates of *E. coli*, 4 isolates of *K. pneumoniae*, and 1 isolate of *E. amnigenus* ([Table 2](#T2){ref-type="table"}). The rate of non-susceptibility to carbapenems was 1.22%. Fifteen of the 18 isolates (83.3%) were resistant to ertapenem (≥8 mg/L) and only 2 of the 18 isolates (11.1%) were resistant to imipenem (≥16 mg/L). All of the isolates exhibited multidrug-resistance to the antibiotics tested (data not shown).

2. Screening of carbapenemases
------------------------------

Of the 18 carbapenem-resistant isolates, 9 tested positive in MHT and 6 positive in the EDTA-disc synergy tests, indicating the production of class B carbapenemases in these strains ([Table 2](#T2){ref-type="table"}). None of them tested positive in the clavulanic acid-disc synergy tests, indicating the absence of class A carbapenemases.

3. PCR amplification and sequence analysis
------------------------------------------

Carbapenemase genes were detected in 10 of the 18 carbapenem-resistant isolates; the genes included the *bla*~IMP-8~ gene from 4 *E. cloacae* isolates and 2 *K. pneumoniae* isolates; the *bla*~IMP-26~ gene from 1 *E. cloacae* isolate; the *bla*~oxa-1~ gene from 5 *E. cloacae* isolates and 2 *E. coli* isolates; and the *bla*~oxa-47~ gene from 2 *K. pneumoniae* isolates ([Table 2](#T2){ref-type="table"}). We failed to detect *bla*~SME~, *bla*~KPC~, *bla*~NDM-1~, or *bla*~VIM~ type carbapenemase genes in these 18 isolates. ESBL genes were found in all the isolates except for the 2 *E. cloacae* isolates that harbored the *bla*~IMP-8~ gene. AmpC cephalosporinase genes were detected in 7 of the 18 isolates: including the *bla*~DHA-1~ gene from 2 *K. pneumoniae* isolates; the *bla*~ACT-1~ gene from 1 *E. cloacae* isolate and 1 *E. amnigenus* isolate; and the *bla*~CMY-2~ gene from 3 *E. coli* isolates. All the AmpC-positive strains, except for 1 *E. cloacae* strain (No. 1), did not harbor carbapenemase genes.

4. Strain genotyping and epidemiological association
----------------------------------------------------

Genetic relatedness of all the isolates, except for *E. amnigenus*, was investigated by ERIC-PCR typing. Five distinct ERIC profiles were observed amongst 8 strains of *E. cloacae*, and no obvious clonal association was observed within these strains. Five strains of *E. coli* exhibited 2 distinct ERIC profiles, and the 3 strains presenting the same profile, i.e. showing clonal association, were all isolated from the urologic surgery department. Four strains of *K. pneumoniae* showed 2 ERIC profiles and an epidemiological relationship was not found ([Fig. 1](#F1){ref-type="fig"}). However, the 2 strains with identical carbapenemase genes, ESBL and AmpC cephalosporinase, exhibited the same ERIC profile.

DISCUSSION
==========

Since the widespread use of carbapenems in the clinic, carbapenem-resistant *Enterobacteriaceae* species have been detected increasingly worldwide, and a similar trend has been observed in China \[[@B9]\]. Effective and accurate screening for *Enterobacteriaceae* species with decreased susceptibility to carbapenems is important in routine clinical microbiology tests. In this study, we found that the resistance rate of ertapenem was much higher than that of imipenem (83.3% vs. 11.1%, *P*\<0.01) in the *Enterobacteriaceae* species isolates studied, indicating that ertapenem was more sensitive than imipenem in the screening of carbapenem-unsusceptible *Enterobacteriaceae* species isolates \[[@B11]\]. Nine of 10 strains of *Enterobacteriaceae* species with carbapenemase genes tested positive in MHT, while none of the strains without any carbapenemase genes tested positive in MHT. The sensitivity and specificity of MHT were 90% and 100%, respectively. Six of 7 strains of *Enterobacteriaceae* species with class B carbapenemase tested positive in the EDTA-disc synergy tests, while none of the strains without class B carbapenemase genes tested positive in the EDTA-disc synergy tests. The sensitivity and specificity of the EDTA-disc synergy tests for MBLs detection were 85.7% and 100%, respectively.

In the 10 strains of *Enterobacteriaceae* species with carbapenemase genes, 4 strains harbored the *bla*~IMP-8~ and *bla*~oxa-1~ genes, 2 strains harbored the *bla*~IMP-8~ and *bla*~oxa-47~ genes, and 3 strains harbored the *bla*~oxa-1~ gene alone. These results suggest that the most common carbapenemase-type genes in our hospital were *bla*~IMP-8~ (6/9) and *bla*~oxa-1~ (7/9). Class A carbapenemase genes and VIM and NDM-1 β-lactamase genes were not detected in our hospital.

The *bla*~IMP-8~ gene, first found in *K. pneumoniae* in 2001, is very closely related to *bla*~IMP-2~ in DNA sequence, with only 4 nucleotide differences between them. This results in 2 amino acid changes. In contrast to the *bla*~IMP-2~ gene, which is located on the chromosome, the *bla*~IMP-8~ cassette is located on the plasmid, which would facilitate the spread of the resistance gene \[[@B24]\] and infection outbreak \[[@B25], [@B26]\]. Like *bla*~IMP-8~, class D carbapenemase can only weakly hydrolyze imipenem. All strains with *bla*~OXA~ carbapenemase genes in our study were susceptible to imipenem except for one *E. coli* isolate (No.12), suggesting that this strain might have other drug-resistant mechanisms, such as loss or lower expression of major porins. In this study, we simultaneously detected *bla*~IMP-8~ and *bla*~OXA-1~ in 4 strains of *E. cloacae*. This observation has not been previously reported in China.

Biochemical analysis showed that CMY-2 and ACT-1 β-lactamase had a high catalytic efficiency towards imipenem, with low observed *Km* values. CMY-2, ACT-1, and DHA-1 β-lactamases conferred a high level of resistance to ceftazidime and cefotaxime and significantly reduced the susceptibility to imipenem once expressed in *E. coli* HB4, whilst FOX-1 and ACC-1 enzymes did not confer resistance to imipenem \[[@B21]\]. In our study, 6 of the 9 MHT-negative strains expressed AmpC cephalosporinase genes, including *bla*~ACT-1~ in 1 *E. cloacae* strain, *bla*~CMY-2~ in 3 *E. coli* strains, and *bla*~DHA-1~ in 2 *K. pneumoniae* strains. The *bla*~FOX-1~ and *bla*~ACC-1~ genes were not found. This observation suggests that AmpC cephalosporinase hyperproduction may contribute to the resistance observed in these isolates \[[@B4]\]. Five strains were not found to contain any carbapenemase or AmpC cephalosporinase genes, implying that resistance in these strains may involve other mechanisms not investigated in this study.

ERIC-PCR studies demonstrated that the infections caused by 8 strains of *E. cloacae* were spontaneous, because of the absence of genetic relatedness between these strains. Three of 5 *E. coli* strains isolated from the urologic surgery ward showed the same genotype, suggesting a possible clonal dissemination of 1 strain. Although we did not find an obvious clonal association among 4 strains of *K. pneumoniae*, the finding of 2 strains with completely identical ERIC profile and drug-resistant gene profile suggests there is a possibility for these to become a clonal prevalence.

Interestingly, strains expressing the *bla*~IMP~ carbapenemase genes were not isolated from patients hospitalized in any department in the hospital except the department of surgery, and all the patients with positive of *bla*~IMP~ carbapenemase genes had received surgery. Surgery has been reported to be an important risk factor for the acquisition of MBL producers \[[@B25]\]. The finding of carbapenem-resistant isolates only in the department of surgery in our hospital may have important implications for the prevention and dissemination control of these drug-resistant pathogens. Because it is likely that the strains of *Enterobacteriaceae* species with decreased susceptibility to carbapenems might be prevalent in the department of surgery in our hospital, strict infection control measures should be implemented in order to prevent infection dissemination.
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Oligonucleotides used as primers for PCR and sequencing in this study
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Abbreviations: *E. cloacae*, *Enterobacter cloacae*; *E. amnigenus*, *Enterobacter amnigenus*; *E. coli*, *Escherichia coli*; *K. pneumoniae*, *Klebsiella pneumoniae*; ETP, Ertapenem; IMP, Imipenem; MHT, modified Hodge test; ICU, intensive care unit.
